259 related articles for article (PubMed ID: 18599104)
1. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
[TBL] [Abstract][Full Text] [Related]
2. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
3. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
5. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
8. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
9. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
[TBL] [Abstract][Full Text] [Related]
10. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity.
Yu FH; Wang CT
Retrovirology; 2018 Apr; 15(1):32. PubMed ID: 29655366
[TBL] [Abstract][Full Text] [Related]
12. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
[TBL] [Abstract][Full Text] [Related]
13. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
14. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
15. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
Su CT; Kwoh CK; Verma CS; Gan SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
[TBL] [Abstract][Full Text] [Related]
16. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
Robinson LH; Gale CV; Kleim JP
J Virol Methods; 2002 Jul; 104(2):147-60. PubMed ID: 12088824
[TBL] [Abstract][Full Text] [Related]
18. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
[TBL] [Abstract][Full Text] [Related]
19. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
[TBL] [Abstract][Full Text] [Related]
20. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]